Techbio company Qureight has appointed Rebecca Simmons as the company’s Chief Operating Officer. 

Simmons will be responsible for scaling the company’s global business operations and leading sustainable growth initiatives. The appointment comes as Qureight aims to drive adoption and integration of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials for lung and heart diseases.  

Simmons was previously COO at quantum computing company Riverlane, having also worked as Deputy Director and Co-Founder of THIS Institute (The Healthcare Improvement Studies Institute).  

“Qureight’s pioneering AI-powered CT imaging biomarkers and data management platform is enabling real insights to be drawn from complex and diverse health data, to ultimately deliver real impact for patients,” said Simmons.  

“The team is already incredible, with an expert team of clinicians, scientists and machine learning engineers. I’m delighted to join the company and am looking forward to an exciting year!” 

“Rebecca’s experience, expertise and people-centric leadership approach will be instrumental in supporting the team as we scale the company, accelerating our mission to advance the understanding of lung and heart disease,” commented Muhunthan Thillai, MD, Co-Founder and CEO of Qureight. 

“Her blend of rigorous academic training with commercial acumen made Rebecca the natural choice to lead this next chapter of growth for Qureight. Welcome to the team, Rebecca.” 

Bruno Quinney, Content Team, DDW